ReviewClinical and experimental hepatology2025
Steatotic liver disease and chronic viral hepatitis.
Review in Clinical and experimental hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Liver-Bone Axis in Steatotic Liver Disease.Calcified tissue international · 2026Review
- Risk of Liver and Non-Liver Malignancy in HCV-Infected Patients with Cirrhosis After Direct-Acting Antiviral Treatment.Cancers · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Steatotic liver disease (SLD) is a condition characterized by excessive fat accumulation within hepatocytes. In recent years, the nomenclature and diagnostic framework of the disease have evolved and the term SLD has replaced the previous fatty liver disease classification. This change reflects a more inclusive understanding of the metabolic drivers of the disease and its strong association with systemic conditions. With the rising global prevalence of metabolic disorders, the burden of SLD has increased significantly, making it the leading cause of chronic liver disease worldwide. While many cases of SLD remain non-progressive, metabolic dysfunction associated steatohepatitis (MASH) may advance to fibrosis, cirrhosis, or hepatocellular carcinoma. The risk of disease progression may be greater when liver steatosis coexists with other hepatic insults, particularly chronic infections with hepatitis B virus or hepatitis C virus. This review explores the prevalence, interactions, and therapeutic implications of SLD in patients with chronic viral hepatitis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.